Get the Stockscreener App
629.82
1.13%
6.2781
Regeneron Pharmaceuticals Inc stock is traded at $629.82, with a volume of 39,369.
It is up +1.13% in the last 24 hours and up +4.98% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
See More
Previous Close:
$623.54
Open:
$629.9
24h Volume:
39,369
Relative Volume:
0.04
Market Cap:
$66.08B
Revenue:
$14.92B
Net Income/Loss:
$4.42B
P/E Ratio:
15.35
EPS:
41.0422
Net Cash Flow:
$3.79B
1W Performance:
+1.15%
1M Performance:
+4.98%
6M Performance:
-18.30%
1Y Performance:
+17.89%
1-Day Range:
$627.22
$632.85
1-Week Range:
$619.70
$638.76
52-Week Range:
$529.69
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
630.31 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
497.51 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
921.65 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.83 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
183.46 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Resumed | Piper Sandler | Overweight |
| Mar-06-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme - Pharmaceutical Technology
Element Squared LLC Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA selects seven companies including Eli Lilly and Regeneron for accelerated manufacturing review pilot - grafa.com
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Benzinga
Regeneron opens the week with analyst focus, shares on NASDAQ radar - AD HOC NEWS
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Is Regeneron Pharmaceuticals, Inc. (REGN) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds? - Insider Monkey
RBC Capital Maintains a Sector Perform Rating on Regeneron (REGN) – Here’s Why - Insider Monkey
How the president of Regeneron pursued his American dream - New York Post
Regeneron clears key moving averages, shares trade below consensus targets - Ad-hoc-news.de
Pictet Asset Management Holding SA Sells 30,616 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The EYLEA injection from Regeneron Pharmaceuticals Inc.high-dose eye therapy pushes into diabetic - Ad-hoc-news.de
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested - Yahoo Finance
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
How Investors May Respond To Regeneron Pharmaceuticals (REGN) Cemdisiran Priority Review for gMG Treatment - simplywall.st
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron myasthenia gravis therapy undergoes US and EU review - MSN
why dominant pharmaceutical firms are paying billion dollar premiums for immunology assets - grafa.com
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance - Investorideas.com
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), AbSci (ABSI) and Viking Therapeutics (VKTX) - The Globe and Mail
Aethlon Medical tracks Ebola outbreak, readies Hemopurifier talks - Stock Titan
Louisiana State Employees Retirement System Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron highlights robust pipeline progress, shares trade in a neutral technical range - Ad-hoc-news.de
Enterprise value to revenue forward of Regeneron Pharmaceuticals, Inc. – GETTEX:RGO - TradingView
Price to earnings forward of Regeneron Pharmaceuticals, Inc. – NASDAQ:REGN - TradingView
The EYLEA Injection from Regeneron Pharmahigh-dose eye therapy targets chronic retinal disease - Ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:REGN) - TradingView
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast - The Manila Times
Regeneron schedules July 30 earnings call and webcast - Stock Titan
REGNUS Forecast — Price Target — Prediction for 2027 - TradingView
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $788 - Moomoo
Assenagon Asset Management S.A. Has $160.54 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Prominent construction companies get a portion of Regeneron's $2B Saratoga expansion - The Business Journals
Will Priority-Reviewed Quarterly siRNA gMG Therapy Change Regeneron Pharmaceuticals' (REGN) Narrative? - Yahoo Finance
(REGN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
BI Asset Management Fondsmaeglerselskab A S Sells 2,968 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc (REGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Regeneron Pharmaceuticals (REGN) Leans On Pipeline Promise As Undervaluation Case Stays In Focus - simplywall.st
Regeneron (REGN) Advances Cemdisiran for Myasthenia Gravis with Regulatory Approvals - GuruFocus
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Regeneron's Applications for gMG Drug Accepted by FDA and EMA - Yahoo Finance
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Regeneron (REGN) and Alkermes (ALKS) - The Globe and Mail
Regeneron highlights RNAi drug submissions, shares trade in Nasdaq range - AD HOC NEWS
Emerging Stars in Weight Loss: Regeneron and Amgen - Intellectia AI
2 Underrated Weight Loss Stocks to Buy and Hold - The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Institutional Confidence - TradingKey
Is Regeneron Pharmaceuticals stock underperforming the Dow? - MSN
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
3.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):